SCHEMBL7574583

SCHEMBL7574583

CCOc1ccc(-c2ccc(C(=O)CC(CCN3C(=O)c4ccccc4C3=O)(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HPGD P15428 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 1/20 0.42
RPS6KA2 Q15349 1/20 0.41
LMNA P02545 1/20 0.41
MMP2 P08253 4/20 0.41
MMP9 P14780 4/20 0.41
MMP3 P08254 2/20 0.40
MMP13 P45452 2/20 0.40
GAA P10253 2/20 0.39
MMP1 P03956 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296941 0.89 NPC1 (0.42) MEN1KMT2AHPGDALDH1A1NPC1
SCHEMBL6293053 0.88 MMP2 (0.43) ALDH1A1NPC1RPS6KA2MMP2MMP9
SCHEMBL7893148 0.79 SMN1; SMN2 (0.55) MEN1KMT2AHPGDALDH1A1NPC1
SCHEMBL7860396 0.77 NPC1 (0.60) MEN1KMT2AALDH1A1NPC1RPS6KA2
SCHEMBL7861865 0.73 THRA (0.41) HPGDGAANPSR1MAPTRAB9A
SCHEMBL30249505 0.72 MMP2 (0.56) MEN1KMT2AHPGDALDH1A1NPC1
SCHEMBL4318837 0.72 MMP2 (0.56) MEN1KMT2AHPGDALDH1A1NPC1
SCHEMBL9226627 0.72 MEN1 (0.46) MEN1KMT2ALMNAMAPTRAB9A
SCHEMBL7580305 0.69 HTT (0.45) MEN1KMT2AHPGDALDH1A1NPC1
SCHEMBL7862778 0.68 GSK3B (0.59) MEN1KMT2AALDH1A1NPC1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140768-A1 USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES Bayer Aktiengesellschaft (DE) 2001-10-10 EP disclosed
WO-2000040539-A1 USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2000-07-13 WO disclosed